Since AML-NK patients represent the largest subgroup of adult AML patients, and since it is defined as a group with intermediate risk, we wanted to examine whether the analysis of GAS5 expression can contribute to a more accurate risk stratification. Here, GAS5 is linked to acute myeloid leukemia.